Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FTH gained 34.8% through September 1 and closed near its period high. The FDA's Fast Track designation for PIKTOR plus paclitaxel provides a recent oncology catalyst, with additional PK/PD and clinical milestones capable of sustaining attention.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Ongoing Cash Burn ⢠Dilution Risk FTH offers strong liquidity and minimal leverage, but absent revenue, persistent losses, cash burn, and dilution risk make it highly speculative.
Price Behavior
Key Price Behavior Insights: ⢠Higher overall trend ⢠$32 support test ⢠$34.71 resistance Support Level: $32.00â$33.00; deeper support $28.55â$29.40 Resistance Level: $34.50â$34.71 FTH remains bullish over the last month, with a breakout above $34.71 favoring further gains while a drop below $32.00 risks a pullback toward $28.55â$29.40.
Sentiment & News
Key News Insights: ⢠FDA Fast Track ⢠Trial Dose Modeling ⢠Leadership Expansion Faeth's Fast Track designation for PIKTOR, ongoing trial progress, and strengthened leadership support a positive clinical and regulatory outlook.
AI Summary
FTH is a well-funded but highly concentrated clinical bet on PIKTOR, so investors should treat the recent rally as catalyst-driven exposure and require meaningful efficacy and tolerability validation in biomarker-selected endometrial cancer before underwriting further upside, while monitoring burn and dilution.
Description
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies intended to improve outcomes for cancer patients by inhibiting multiple nodes in key oncogenic signaling pathways. Its lead program, PIKTOR, is an investigational all-oral combination therapy designed to target the PI3K/AKT/mTOR pathway.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 1 | Sep 8 | FTH | Faeth Therapeutics, Inc. | FTH gained 34.8% through September 1 and closed near its period high. The FDA's Fast Track designation for PIKTOR plus paclitaxel provides a recent oncology catalyst, with additional PK/PD and clinical milestones capable of sustaining attention. | Active | +0.0% |